Effect of aqueous extract of Tribulus terrestris on the activity of major platelets factors and the treatment of immune thrombocytopenic purpura

Document Type : Original research paper

Authors

1 Student Research Committee, Kermanshah University of Medical Sciences, Kermanshah, Iran

2 Medical Biology Research Center, Health Technology Institute, Kermanshah University of Medical Sciences, Kermanshah, Iran

3 Department of Internal Medicine, School of Medicine, Kermanshah University of Medical Sciences, Kermanshah, Iran

4 Medical Biology Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran

5 Department of Laboratory Sciences, School of Allied Medical Sciences, Abadan University of Medical Sciences, Abadan, Iran

Abstract

introduction: Idiopathic thrombocytopenic purpura (ITP), an autoimmune disease with decreased platelet counts needs corticosteroids, intravenous immunoglobulin (IVIg), and anti-Rho in the first line and splenectomy, rituximab, and thrombopoietin in the second line of therapy. The present study reveals the application of the aqueous extract Tribulus terrestris (T. terrestris) plant in ITP treatment.
Methods:  A standard aqueous extract of T. terrestris was given orally to twenty patients who were newly diagnosed with ITP in the form of 500 mg capsules (three times per day for14 days). Blood samples were taken from patients before, during, and after two weeks of treatment to count plasma Platelet Factor 4 (PF4), serotonin factor, and Von Willebrand Factor (VWF).
Results: We observed a significant increase in the platelet count among all patients, while plasma platelets and assay factor 4 decreased and VWF increased during and after treatment. Serotonin was increased on days 1 and 14 and slightly decreased once the treatment was completed. 
Conclusion: Our findings suggest that T. terrestris extract can be considered an efficient alternative medicine for the treatment of ITP.

Keywords

References

1. Von Dem Borne AEK, Ouwehand WH. 11 Immunology of platelet disorders. Bailliere’s clinical haematology.  1989;2(3):749-81.
2. Karpatkin S. Autoimmune thrombocytopenic purpura. 1980.
3. Chong BH. Diagnosis, treatment and pathophysiology of autoimmune thrombocytopenias. Critical reviews in oncology/hematology. 1995;20(3):271-96.
4. Lo E, Deane S. Diagnosis and classification of immunemediated thrombocytopenia. Autoimmunity reviews. 2014;13(4-5):577-83.
5. Peyvandi F, Garagiola I, Baronciani L. Role of von Willebrand factor in the haemostasis. Blood Transfusion. 2011;9(Suppl 2):s3.
6. Beardsley D, Tang C, Chen B-G, Lamborn C, Gomes E, Srimatkandada V. The disulfide-rich region of platelet 
glycoprotein (GP) IIIa contains hydrophilic peptide sequences that bind anti-GPIIIa autoantibodies from patients with immune thrombocytopenic purpura (ITP). Biophysical chemistry. 2003;105(2-3):503-15.
7. Gillis S, Eldor A. 6 Immune thrombocytopenic purpura in adults: clinical aspects. Baillière’s clinical haematology. 1998;11(2):361-72.
8. ITP A. Guidelines for the investigation and management of idiopathic thrombocytopenic purpura in adults, children and in pregnancy. Br J Haematol. 2003;120(1):574-96.
9. Wu G, Jiang S, Jiang F, Zhu D, Wu H, Jiang S. Steroidal glycosides from T. terrestris. Phytochemistry. 1996;42(6):1677-81.
10. Sun W, Gao J, Tu G, Guo Z, Zhang Y. A new steroidal saponin from T. terrestris Linn. Natural Product Letters. 2002;16(4):243-7.
11. Bourke C, Stevens G, CARRIGAN MJ. Locomotor effects in sheep of alkaloids identified in Australian T. terrestris. Australian veterinary journal. 1992;69(7):163-5.
12. Conrad J, Dinchev D, Klaiber I, Mika S, Kostova I, Kraus W. A novel furostanol saponin from T. terrestris of Bulgarian origin. Fitoterapia. 2004;75(2):117-22.
13. Cai L, Wu Y, Zhang J, Pei F, Xu Y, Xie S, et al. Steroidal saponins from T. terrestris. Planta medica. 2001;67(02):196-8.
14. Nikoo M, Hasanpoor Z, Mostafaie A. Effect of T. terrestrisaqueous extract on survival and growth of human peripheral blood mononuclear cells (Hpbmc) and several cancerous cell lines. Journal of Reports in Pharmaceutical Sciences. 2015;4(1):24.
15. McCRAE K. Immune thrombocytopenia: no longer ‘idiopathic’. Cleve Clin J Med. 2011;78(6):358.
16. Li M, Wu W-K, Liu L, Liao F-L, Shinohara Y, Handa S, et al. Specific inhibiting effects of Ilexonin A on von Willebrand factor-dependent platelet aggregation under high shear rate. Chinese medical journal. 2004;117(2):241-6.
17. Bing Z, Xiaoqing L, Jinghong H. The Effects of Chicory Extract on the Levels of vWF, ET, TXA_2, PGI_2 and the Ratio of PGI_2/TXA_2 in the Rabbit Model of Hyperglycemia with Hyperlipidemia [J]. Journal of Beijing University of Traditional Chinese Medicine. 2000;6.
18. WHITE JG. The dense bodies of human platelets: inherent electron opacity of the serotonin storage particles. Blood. 1969;33(4):598-606.
19. Canobbio I, Bertoni A, Lova P, Paganini S, Hirsch E, Sinigaglia F, et al. Platelet activation by von Willebrand factor requires coordinated signaling through thromboxane A2 and FcγIIA receptor. J Biol Chem. 2001;276(28):26022-9.
20. Mercado CP, Kilic F. Molecular mechanisms of SERT in platelets: regulation of plasma serotonin levels. Molecular interventions. 2010;10(4):231.
21. KIMURA Y, OKUDA H, ARICHI S. Effects of various ginseng saponins on 5‐hydroxytryptamine release and aggregation in human platelets. Journal of pharmacy and pharmacology. 1988;40(12):838-43

Files

History

  • Receive Date: 28 September 2021
  • Revise Date: 10 November 2021
  • Accept Date: 13 November 2021
  • First Publish Date: 13 November 2021

Share

How to cite

Statistics